These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37308105)

  • 1. Insulin Secretion Capacity as a Crucial Feature to Distinguish Type 1 From Type 2 Diabetes and to Indicate the Need for Insulin Therapy - A Critical Discussion of the ADA/EASD Consensus Statement on the Management of Type 1 Diabetes in Adults.
    Fritsche A
    Exp Clin Endocrinol Diabetes; 2023 Sep; 131(9):500-503. PubMed ID: 37308105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considering Insulin Secretory Capacity as Measured by a Fasting C-Peptide/Glucose Ratio in Selecting Glucose-Lowering Medications.
    Fritsche A; Heni M; Peter A; Gallwitz B; Kellerer M; Birkenfeld AL; Häring HU; Wagner R
    Exp Clin Endocrinol Diabetes; 2022 Mar; 130(3):200-204. PubMed ID: 32947641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel.
    Buzzetti R; Tuomi T; Mauricio D; Pietropaolo M; Zhou Z; Pozzilli P; Leslie RD
    Diabetes; 2020 Oct; 69(10):2037-2047. PubMed ID: 32847960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis.
    Schernthaner G; Barnett AH; Betteridge DJ; Carmena R; Ceriello A; Charbonnel B; Hanefeld M; Lehmann R; Malecki MT; Nesto R; Pirags V; Scheen A; Seufert J; Sjohölm A; Tsatsoulis A; DeFronzo R
    Diabetologia; 2010 Jul; 53(7):1258-69. PubMed ID: 20352408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.
    Lim CE; Pasternak B; Eliasson B; Danaei G; Ueda P
    Eur J Prev Cardiol; 2023 Jun; 30(8):634-643. PubMed ID: 36582120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycaemic control and implementation of the ADA/EASD-2006 consensus algorithm in type 2 diabetes mellitus patients in primary care in Spain.
    Alvarez-Guisasola F;
    Int J Clin Pract; 2014 Jan; 68(1):28-39. PubMed ID: 24341300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do published ADA studies support the ADA-EASD position statement for the management of hyperglycaemia in type 2 diabetics?
    Rimareix F; Bauduceau B
    Ann Endocrinol (Paris); 2013 Jul; 74(3):207-10. PubMed ID: 23747137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Holt RIG; DeVries JH; Hess-Fischl A; Hirsch IB; Kirkman MS; Klupa T; Ludwig B; Nørgaard K; Pettus J; Renard E; Skyler JS; Snoek FJ; Weinstock RS; Peters AL
    Diabetologia; 2021 Dec; 64(12):2609-2652. PubMed ID: 34590174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for the management of type 2 diabetes: is ADA and EASD consensus more clinically relevant than the IDF recommendations?
    Czupryniak L
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S22-5. PubMed ID: 20115928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interpretation of the management of type 1 diabetes in adults: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) in 2021].
    Tang XH; Lin XX; Li X; Zhou ZG
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(16):1139-1147. PubMed ID: 35462497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Davies MJ; D'Alessio DA; Fradkin J; Kernan WN; Mathieu C; Mingrone G; Rossing P; Tsapas A; Wexler DJ; Buse JB
    Diabetologia; 2018 Dec; 61(12):2461-2498. PubMed ID: 30288571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical utility of C-peptide measurement in the care of patients with diabetes.
    Jones AG; Hattersley AT
    Diabet Med; 2013 Jul; 30(7):803-17. PubMed ID: 23413806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Inzucchi SE; Bergenstal RM; Buse JB; Diamant M; Ferrannini E; Nauck M; Peters AL; Tsapas A; Wender R; Matthews DR
    Diabetologia; 2012 Jun; 55(6):1577-96. PubMed ID: 22526604
    [No Abstract]   [Full Text] [Related]  

  • 15. The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Holt RIG; DeVries JH; Hess-Fischl A; Hirsch IB; Kirkman MS; Klupa T; Ludwig B; Nørgaard K; Pettus J; Renard E; Skyler JS; Snoek FJ; Weinstock RS; Peters AL
    Diabetes Care; 2021 Nov; 44(11):2589-2625. PubMed ID: 34593612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. To what extent is the new position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) 'personalised'?
    Ceriello A; Gallo M; Gentile S; Giorda CB; De Micheli A;
    Diabetologia; 2012 Oct; 55(10):2853-2855. PubMed ID: 22801904
    [No Abstract]   [Full Text] [Related]  

  • 17. Potential role of oral DPP-4 inhibitors in the ADA/EASD consensus statement algorithm for achieving and maintaining tight glycaemic control in type 2 diabetes: recommendations for oral antidiabetic agents.
    Barnett A
    Int J Clin Pract Suppl; 2007 Aug; (154):12-8. PubMed ID: 17593273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-mixed/split insulin regimen: a serious omission in the ADA/EASD position statement.
    Davidson MB
    Diabetes Care; 2014; 37(1):3-4. PubMed ID: 24356589
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications.
    Scheen AJ; Castillo MJ; Lefèbvre PJ
    Diabetes Metab; 1996 Dec; 22(6):397-406. PubMed ID: 8985647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A decision support tool for appropriate glucose-lowering therapy in patients with type 2 diabetes.
    Ampudia-Blasco FJ; Benhamou PY; Charpentier G; Consoli A; Diamant M; Gallwitz B; Khunti K; Mathieu C; Ridderstråle M; Seufert J; Tack C; Vilsbøll T; Phan TM; Stoevelaar H
    Diabetes Technol Ther; 2015 Mar; 17(3):194-202. PubMed ID: 25347226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.